TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05254691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sprinting
Description: The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung.
Study: NCT00054275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
Study: NCT02556112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Lifestyle Balance
Description: The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Better Body Better Life
Description: The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness Improvement Program
Description: The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
Study: NCT03821805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot reflexology massage
Description: Foot reflexology technique of Father Josef was used as massage intervention
Study: NCT02188667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Providers of Novel Care
Description: Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Providers of Usual Care
Description: Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
Study: NCT03304132

Intervention type: OTHER
Intervention: Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach
Description: The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.

Intervention type: OTHER
Intervention: Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach
Description: The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.

Intervention type: OTHER
Intervention: Classification of Oral Microbiome Using taxonomic approach
Description: The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.

Intervention type: OTHER
Intervention: Classification of Oral Microbiome Using taxonomic approach
Description: The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
Study: NCT03833531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImRS
Description: ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ImRS
Description: ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFT
Description: SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
Study: NCT00824993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
Study: NCT00028756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT01034410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1411
Description: AS1411 40mg/kg/day or AS1411 80mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1411
Description: AS1411 40mg/kg/day or AS1411 80mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2g/m2 bid Days 4-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2g/m2 bid Days 4-7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine 2g/m2 bid Days 4-7
Study: NCT03097653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision-aid
Description: Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard information
Description: Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
Study: NCT02157766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Meditation Practice
Description: Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: 8 week class designed to enhance well-being through training in mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: 8 week class designed to enhance well-being through training in mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: 8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
Study: NCT02267629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel (formerly GLYX-13)
Description: 10 mg/kg IV Rapastinel (formerly GLYX-13)
Study: NCT01304485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Acetate C11
Description: PET Imaging with Sodium Acetate C11
Study: NCT02361528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim: Leukine (Genzyme USA)
Description: Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
Study: NCT00824993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin Supplements
Description: Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin Supplements
Description: Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months
Study: NCT02361528

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo subcutaneously, for 5 days
Study: NCT04403321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tacrolimus)
Description: placebo will be given at 1mg bid.
Study: NCT01079871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 114657 (ORB Preserved Ocular Emulsion)
Description: Patients will dose as needed throughout the day (PRN) for 4 weeks.
Study: NCT01638338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web assisted brief motivational interview on risky drinking
Description: People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to Face
Description: The counseling provided by the GPs will be done at month 0, 6, 12
Study: NCT02118428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol-treated Whole Blood
Description: Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Untreated Whole Blood
Description: Transfusion with untreated fresh Whole Blood
Study: NCT01962558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS Treatment
Description: VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VNS Control
Description: This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
Study: NCT02580370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Topical botulinum toxin type A

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Topical placebo comparator
Study: NCT03918343

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: blood samples (4 times; 14ml per visit)
Study: NCT03435549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote monitoring plus goal setting and social support
Description: Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
Study: NCT03913078

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Fitness
Description: Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PlayFit
Description: Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
Study: NCT01204866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valortim and selected Components
Description: * Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valortim and Selected Components
Description: • It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively
Study: NCT00909636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333
Description: See arm description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333
Description: See arm description for more information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description for more information
Study: NCT00706966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: 6 months of dutasteride 3.5 mg daily
Study: NCT03766503

Intervention type: OTHER
Group type: OTHER
Intervention: Daily
Description: The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
Study: NCT02156427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITICELL
Description: graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: hyaluronic acid alone
Study: NCT00854503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 20 mg/day in one oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20 mg/day in one oral administration.
Study: NCT04571112

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)
Description: This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)
Description: This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
Study: NCT01251133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVH0101 (Hib vaccine)
Description: 0.5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™ Vaccine
Description: 0.5mL
Study: NCT02718638

Intervention type: OTHER
Group type: OTHER
Intervention: physical exercises
Description: Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
Study: NCT00958776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir+SOC
Description: * Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+SOC
Description: Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Study: NCT04349501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restriction Spectrum Imaging Magnetic Resonance Imaging
Description: RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
Study: NCT01281475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
Study: NCT00054639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04910191

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electronic stethoscope
Description: Electronic stethoscope
Study: NCT00331929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minato A 500 AS spirometer
Description: Spirometry at rest
Study: NCT04114591

Intervention type: PROCEDURE
Intervention: anterior resection
Description: The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed

Intervention type: PROCEDURE
Intervention: anterior resection
Description: The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
Study: NCT02047474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV